Axitinib for the treatment of metastatic renal cell carcinoma.

about

Decreased WWOX expression promotes angiogenesis in osteosarcoma.A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma.

P2860

Q42365252-B07FD1D3-20EA-4AA5-B78D-6BA974669B23 Q47143379-C73759E9-B995-4C71-8451-B35478E4BC0F

P2860

Axitinib for the treatment of metastatic renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q38697227

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Axitinib for the treatment of metastatic renal cell carcinoma.

@en

type

Item

label

Axitinib for the treatment of metastatic renal cell carcinoma.

@en

prefLabel

Axitinib for the treatment of metastatic renal cell carcinoma.

@en

P1476

Axitinib for the treatment of metastatic renal cell carcinoma

@en

P2093

Brian Rini

http://www.w3.org/2001/XMLSchema#string

Julianne Griswold

http://www.w3.org/2001/XMLSchema#string

P2860

Axitinib for the management of metastatic renal cell carcinoma

Axitinib in Metastatic Renal Cell Carcinoma

Cancer statistics, 2015

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

P304

303-311

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.15.322

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hiral D Parekh

P577

2016-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26769075

http://www.w3.org/2001/XMLSchema#string

Axitinib for the treatment of metastatic renal cell carcinoma.

about

P2860

P2860

Axitinib for the treatment of metastatic renal cell carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698